查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1592037

卡波西氏肉瘤市场：按类型、药物类别、治疗方法、治疗方式 - 全球预测 2025-2030

Kaposi Sarcoma Market by Type (Classic Kaposi Sarcoma, Endemic Kaposi Sarcoma, Epidemic Kaposi Sarcoma), Drug Class (Doxil, Doxorubicin Hydrochloride Liposome, Intron A ), Treatment, Mode of Treatment - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年卡波西氏肉瘤市场价值为1.4029亿美元，预计2024年将达到1.4555亿美元，复合年增长率为3.73%，到2030年将达到1.814亿美元。

卡波西氏肉瘤是一种在血管和淋巴管内壁形成的癌症，通常出现在皮肤和黏膜上。这个市场的需求和范围集中在对先进诊断、有效治疗方法和个人化治疗的迫切需要，特别是考虑到免疫力缺乏的患者（例如爱滋病毒/爱滋病患者）的盛行率。最终用途市场包括医院、研究机构和主要专注于肿瘤学和病毒学的专科诊所。全球癌症发病率上升、分子生物学的进步以及对罕见疾病的认识和支持不断增强，推动了市场成长。主要影响因素包括爱滋病毒的传播、早期检测方法的改进以及政府和非政府的支持措施。值得注意的是，生物技术公司和研究机构之间的合作为治疗方法和药物突破提供了有利可图的机会。然而，挑战包括高昂的研发成本、治疗的潜在副作用以及扩大获得全面医疗保健的机会的需要，特别是在新兴市场。此外，一般人群对卡波西肉瘤的认识和理解有限，导致诊断较晚，并使治疗挑战复杂化。有前景的创新领域包括标靶治疗、免疫治疗以及将人工智慧整合到诊断中以提高早期检测率。卡波西氏肉瘤相关疱疹病毒 (KSHV) 的研究为预防策略和新的治疗方法提供了潜力。这个市场的性质是高度专业化的，需要肿瘤学家、病毒学家和药理学家之间持续的多学科合作。捕捉市场机会的研究包括投资尖端研究、促进公私伙伴关係以及加强患者教育和推广计划，以确保早期诊断和遵守治疗方法。儘管市场复杂，但改善全球患者治疗效果的有效创新潜力巨大。

主要市场统计
基准年[2023] 1.4029亿美元
预测年份 [2024] 1.4555亿美元
预测年份 [2030] 1.814 亿美元
复合年增长率（%） 3.73%

市场动态：快速发展的卡波西氏肉瘤市场的关键市场洞察

卡波西氏肉瘤市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 爱滋病毒相关疾病的盛行率增加 卡波西氏肉瘤
    • 接受器官移植的患者数量增加
    • 增加与卡波西氏肉瘤病相关的临床研究
  • 市场限制因素
    • 卡波西氏肉瘤诊断治疗高成本
  • 市场机会
    • 投资卡波西氏肉瘤治疗的研发活动
    • 先进的高效抗逆转滤病毒治疗简介
  • 市场挑战
    • 缺乏技术纯熟劳工和药品供不应求

波特五力：驾驭卡波西氏肉瘤市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解卡波西氏肉瘤市场的外部影响

外部宏观环境因素在塑造卡波西氏肉瘤市场表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解卡波西氏肉瘤市场的竞争格局

卡波西氏肉瘤市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵卡波西氏肉瘤市场供应商的绩效评估

FPNV 定位矩阵是评估卡波西氏肉瘤市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製卡波西氏肉瘤市场的成功之路

卡波西氏肉瘤市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 与爱滋病毒相关的卡波西氏肉瘤盛行率不断上升
      • 接受器官移植手术的患者数量增加
      • 增加与卡波西氏肉瘤病相关的临床研究
    • 抑制因素
      • 卡波西氏肉瘤治疗相关的高诊断成本
    • 机会
      • 投资与卡波西氏肉瘤治疗相关的研发活动
      • 先进的高效抗逆转滤病毒治疗简介
    • 任务
      • 缺乏熟练劳动力和药物供不应求
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章卡波西氏肉瘤市场：依类型

  • 经典（地中海）卡波西氏肉瘤
  • 地方性（非洲）卡波西氏肉瘤
  • 流行病（爱滋病相关）卡波西氏肉瘤
  • 医源性（移植相关）卡波西氏肉瘤

第 7 章按药物类别分類的卡波西氏肉瘤市场

  • Doxil（盐酸阿霉素脂质体）
  • 盐酸阿霉素脂质体
  • 内含子A（重组α干扰素-2b）
  • 紫杉醇
  • Pomalidomide
  • Pomalyst（Pomalidomide）
  • 重组α干扰素-2b
  • 硫酸长春碱

第八章卡波西氏肉瘤治疗市场

  • 生物疗法
  • 化疗
  • 冷冻疗法
  • 心
  • 放射治疗
  • 外科手术
  • 治疗

第九章 卡波西氏肉瘤市场治疗方法

  • 化疗
  • 病灶内注射

第10章美洲卡波西氏肉瘤市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区卡波西氏肉瘤市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲卡波西氏肉瘤市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Aphios Corporation
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Baxter International, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Getwell Oncology Pvt Ltd
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • John Wiley & Sons, Inc.
  • Johnson & Johnson Services, Inc
  • Lupin Ltd.
  • Merck & Co., Inc
  • Mylan NV
  • Navidea Biopharmaceuticals, Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C994FA

The Kaposi Sarcoma Market was valued at USD 140.29 million in 2023, expected to reach USD 145.55 million in 2024, and is projected to grow at a CAGR of 3.73%, to USD 181.40 million by 2030.

Kaposi Sarcoma is a cancer that forms in the lining of blood and lymph vessels and typically appears on the skin or mucosal surfaces. The necessity and application scope in this market center around the urgent need for advanced diagnostics, effective therapeutics, and personalized treatments, especially given its prevalence among immunocompromised patients, such as those with HIV/AIDS. The end-use market predominantly includes hospitals, research institutes, and specialty clinics that focus on oncology and virology. Market growth is driven by the increasing global cancer burden, advancements in molecular biology, and the growing awareness and advocacy around rare diseases. Key influencing factors include the prevalence of HIV, improvements in early detection methods, and governmental and non-governmental support initiatives. Notably, collaborations between biotech companies and research institutions offer lucrative opportunities for breakthroughs in treatment modalities and drug discoveries. However, the market is challenged by the high costs of research and development, potential side effects of treatment, and a need for greater access to comprehensive healthcare, particularly in developing regions. Additionally, limited awareness and understanding of Kaposi Sarcoma in the general population contribute to late-stage diagnoses, compounding treatment challenges. Promising areas of innovation include targeted therapies, immunotherapies, and the integration of AI in diagnostics to improve early detection rates. Research on Kaposi Sarcoma-associated herpes virus (KSHV) offers potential for preventive strategies and novel therapeutic approaches. The nature of the market is highly specialized, requiring ongoing cross-disciplinary collaborations among oncologists, virologists, and pharmacologists. Recommendations for capturing market opportunities involve investing in cutting-edge research, fostering partnerships between public and private sectors, and enhancing patient education and outreach programs to ensure early diagnosis and adherence to treatment regimens. Despite the market complexities, there lies tremendous potential for impactful innovations that can improve patient outcomes globally.

KEY MARKET STATISTICS
Base Year [2023] USD 140.29 million
Estimated Year [2024] USD 145.55 million
Forecast Year [2030] USD 181.40 million
CAGR (%) 3.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Kaposi Sarcoma Market

The Kaposi Sarcoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of HIV-associated Kaposi Sarcoma
    • Rising number of patients undergoing organ transplantation procedures
    • Growing number of clinical studies related to Kaposi Sarcoma disease
  • Market Restraints
    • High cost associated with diagnosis of Kaposi Sarcoma treatment
  • Market Opportunities
    • Investment in R&D activities for Kaposi Sarcoma treatment
    • Introduction of advanced highly active antiretroviral treatment
  • Market Challenges
    • Lack of skilled workforce and shortage in the supply of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Kaposi Sarcoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Kaposi Sarcoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Kaposi Sarcoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Kaposi Sarcoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Kaposi Sarcoma Market

A detailed market share analysis in the Kaposi Sarcoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Kaposi Sarcoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Kaposi Sarcoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Kaposi Sarcoma Market

A strategic analysis of the Kaposi Sarcoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Kaposi Sarcoma Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals LLC, Aphios Corporation, Aurobindo Pharma Limited, Bausch Health Companies Inc., Baxter International, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Getwell Oncology Pvt Ltd, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, John Wiley & Sons, Inc., Johnson & Johnson Services, Inc, Lupin Ltd., Merck & Co., Inc, Mylan N.V., Navidea Biopharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Kaposi Sarcoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, Epidemic (AIDS-associated) Kaposi Sarcoma, and Iatrogenic (Transplant-Related) Kaposi Sarcoma.
  • Based on Drug Class, market is studied across Doxil (Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride Liposome, Intron A (Recombinant Interferon Alfa-2b), Paclitaxel, Pomalidomide, Pomalyst (Pomalidomide), Recombinant Interferon Alfa-2b, and Vinblastine Sulfate.
  • Based on Treatment, market is studied across Biological Therapy, Chemotherapy, Cryosurgery, HAART, Radiation Therapy, Surgery, and Treatment.
  • Based on Mode of Treatment, market is studied across Chemotherapy and Intralesional Injection.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of HIV-associated Kaposi Sarcoma
      • 5.1.1.2. Rising number of patients undergoing organ transplantation procedures
      • 5.1.1.3. Growing number of clinical studies related to Kaposi Sarcoma disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with diagnosis of Kaposi Sarcoma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Investment in R&D activities for Kaposi Sarcoma treatment
      • 5.1.3.2. Introduction of advanced highly active antiretroviral treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled workforce and shortage in the supply of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Kaposi Sarcoma Market, by Type

  • 6.1. Introduction
  • 6.2. Classic (Mediterranean) Kaposi Sarcoma
  • 6.3. Endemic (African) Kaposi Sarcoma
  • 6.4. Epidemic (AIDS-associated) Kaposi Sarcoma
  • 6.5. Iatrogenic (Transplant-Related) Kaposi Sarcoma

7. Kaposi Sarcoma Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Doxil (Doxorubicin Hydrochloride Liposome)
  • 7.3. Doxorubicin Hydrochloride Liposome
  • 7.4. Intron A (Recombinant Interferon Alfa-2b)
  • 7.5. Paclitaxel
  • 7.6. Pomalidomide
  • 7.7. Pomalyst (Pomalidomide)
  • 7.8. Recombinant Interferon Alfa-2b
  • 7.9. Vinblastine Sulfate

8. Kaposi Sarcoma Market, by Treatment

  • 8.1. Introduction
  • 8.2. Biological Therapy
  • 8.3. Chemotherapy
  • 8.4. Cryosurgery
  • 8.5. HAART
  • 8.6. Radiation Therapy
  • 8.7. Surgery
  • 8.8. Treatment

9. Kaposi Sarcoma Market, by Mode of Treatment

  • 9.1. Introduction
  • 9.2. Chemotherapy
  • 9.3. Intralesional Injection

10. Americas Kaposi Sarcoma Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Kaposi Sarcoma Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Kaposi Sarcoma Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amneal Pharmaceuticals LLC
  • 4. Aphios Corporation
  • 5. Aurobindo Pharma Limited
  • 6. Bausch Health Companies Inc.
  • 7. Baxter International, Inc.
  • 8. Bayer AG
  • 9. Bristol-Myers Squibb Company
  • 10. Celgene Corporation
  • 11. Cipla Limited
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche AG
  • 14. Getwell Oncology Pvt Ltd
  • 15. GlaxoSmithKline PLC
  • 16. Hikma Pharmaceuticals PLC
  • 17. John Wiley & Sons, Inc.
  • 18. Johnson & Johnson Services, Inc
  • 19. Lupin Ltd.
  • 20. Merck & Co., Inc
  • 21. Mylan N.V.
  • 22. Navidea Biopharmaceuticals, Inc.
  • 23. Pfizer Inc.
  • 24. Sun Pharmaceutical Industries Ltd.
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. KAPOSI SARCOMA MARKET RESEARCH PROCESS
  • FIGURE 2. KAPOSI SARCOMA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. KAPOSI SARCOMA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. KAPOSI SARCOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. KAPOSI SARCOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. KAPOSI SARCOMA MARKET DYNAMICS
  • TABLE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC (MEDITERRANEAN) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC (AFRICAN) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC (AIDS-ASSOCIATED) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC (TRANSPLANT-RELATED) KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DOXIL (DOXORUBICIN HYDROCHLORIDE LIPOSOME), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DOXORUBICIN HYDROCHLORIDE LIPOSOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTRON A (RECOMBINANT INTERFERON ALFA-2B), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY POMALYST (POMALIDOMIDE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RECOMBINANT INTERFERON ALFA-2B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VINBLASTINE SULFATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BIOLOGICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CRYOSURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HAART, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTRALESIONAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES KAPOSI SARCOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM KAPOSI SARCOMA MARKET SIZE, BY MODE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 200. KAPOSI SARCOMA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 201. KAPOSI SARCOMA MARKET, FPNV POSITIONING MATRIX, 2023